A study employing CRISPR/Cas9 to explore the evolutionary beginnings of some giant viruses finds evidence their large genomes arose from gene duplications.

Prairie voles lacking functional receptors for oxytocin form normal social bonds, a finding that could explain the hormone’s clinical failures.

A biotech startup called Tessera Therapeutics has made a splash with its claims about the trademarked technology. Is the excitement justified?

Natural science research projects were among those promised funding by the now-collapsed crypto exchange’s “effective altruism” foundations.

Immune defense genes in bacteria and archaea can identify viral proteins, a study finds, revealing similarities between the immune systems of prokaryotic and eukaryotic organisms.

The biotech company Verve Therapeutics launched the study with the aim of using base editing to treat a genetic condition that causes high cholesterol and increases a person's risk of developing cardiovascular disease.

There is only one week remaining to submit your new product to vie for a coveted spot in The Scientist’s 2022 competition.

A study finds that CRISPR-Nickase, which changes just one allele of a given gene, improves gene editing efficiency compared with CRISPR-Cas9.

This month marks ten years since CRISPR-Cas9 was repurposed as a gene editing system, so we’re looking back at what has been accomplished in a decade of CRISPR editing.

A new method has allowed researchers to conduct the first gene knock-out and knock-in edits on cockroaches and may extend to many other insects.

A brain area of Aedes aegypti responds specifically to components of human sebum, a study finds.

A first-of-its-kind gene therapy dramatically reduced misfolded protein levels in some clinical trial participants for up to six months and reduced levels in all participants for up to a year.

The US Patent and Trademark Office has once again decided that the institute has priority over the University of California and collaborators regarding intellectual property rights for CRISPR-Cas9 gene editing in eukaryotes. But the fight over the technique isn’t over.